• 1
    Sternberg CN, de Mulder PH, Schornagel JH, et al. Randomized Phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer protocol no. 30924. J Clin Oncol. 2001; 19: 26382646.
  • 2
    von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III study. J Clin Oncol. 2000; 18: 30683077.
  • 3
    Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a Phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1997; 15: 25642569.
  • 4
    Dreicer R, Gustin DM, See WA, Williams RD. Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy. J Urol. 1996; 156: 16061608.
  • 5
    Krege S, Rembrink V, Borgermann C, Otto T, Rubben H. Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a Phase 2 study. J Urol. 2001; 165: 6771.
  • 6
    Roth BJ. Ifosfamide in the treatment of bladder cancer. Semin Oncol. 1996; 23(Suppl 6): 5055.
  • 7
    End DW, Smets G, Todd AV, et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 2001; 61: 131137.
  • 8
    Ayan S, Gokce G, Kilicarslan H, Ozdemir O, Yildiz E, Gultekin EY. K-RAS mutation in transitional cell carcinoma of urinary bladder. Int Urol Nephrol. 2001; 33: 363367.
  • 9
    Cattan N, Saison-Behmoaras T, Mari B, et al. Screening of human bladder carcinomas for the presence of Ha-ras codon 12 mutation. Oncol Rep. 2000; 7: 497500.
  • 10
    Przybojewska B, Jagiello A, Jalmuzna P. H-RAS, K-RAS, and N-RAS gene activation in human bladder cancers. Cancer Genet Cytogenet. 2000; 121: 7377.
  • 11
    Saito S, Hata M, Fukuyama R, et al. Screening of H-ras gene point mutations in 50 cases of bladder carcinoma. Int J Urol. 1997; 4: 178185.
  • 12
    Oxford G, Theodorescu D. The role of Ras superfamily proteins in bladder cancer progression. J Urol. 2003; 170: 19871993.
  • 13
    Crul M, de Klerk GJ, Swart M, et al. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol. 2002; 20: 27262735.
  • 14
    Hudes G, Schol J, Baab J, et al. Phase I clinical and pharmacokinetic trial of the farnesyltransferase inhibitor R115777 on a 21-day dosing schedule [abstract]. Proc Am Soc Clin Oncol. 1999; 18: 156a.
  • 15
    Wang J. Optimal design for linear interpolation of curves. Stat Med. 2001; 20: 24672477.
  • 16
    Zujewski J, Horak ID, Bol CJ, et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol. 2000; 18: 927941.
  • 17
    Perez-Ruixo JJ, Cowan KH, Weiner L, et al. Population Pharmacokinetics of Zarnestra using data from Phase I trials. Ninth Meeting of the Population Approach Group [abstract 21], 2002. Available from URL:∼page/.
  • 18
    Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981; 47: 207214.
  • 19
    Simon R. Optimal two-stage designs for Phase II clinical trials. Control Clin Trials. 1989; 10: 110.
  • 20
    Kaplan EL, Meier P. Non-paramenteric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 21
    Calabro F, Sternberg CN. New drugs and new approaches for the treatment of metastatic urothelial cancer. World J Urol. 2002; 20: 158166.
  • 22
    Adjei AA, Croghan GA, Erlichman C, et al. A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin Cancer Res. 2003; 9: 25202526.
  • 23
    Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999; 17: 31733181.
  • 24
    Lerner EC, Zhang TT, Knowles DB, Qian Y, Hamilton AD, Sebti SM. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines. Oncogene. 1997; 15: 12831288.
  • 25
    Cox AD, Der CJ. Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochim Biophys Acta. 1997; 1333: F51F71.
  • 26
    Sharma S, Kemeny N, Kelsen DP, et al. A Phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. Ann Oncol. 2002; 13: 10671071.
  • 27
    Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a Phase 1 clinical-laboratory correlative trial. Blood. 2001; 97: 33613369.
  • 28
    Cohen SJ, Ho L, Ranganathan S, et al. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol. 2003; 21: 13011306.
  • 29
    Adjei AA, Mauer A, Bruzek L, et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003; 21: 17601766.
  • 30
    Johnston SR, Hickish T, Ellis P, et al. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol. 2003; 21: 24922499.
  • 31
    Adjei AA, Davis JN, Bruzek LM, Erlichman C, Kaufmann SH. Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. Clin Cancer Res. 2001; 7: 14381445.
  • 32
    van Cutsem E, van de Velde H, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol. 2004; 22: 14301438.
  • 33
    Lancet JE, Karp JE. Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. Blood. 2003; 102: 38803889.